Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostate gland. Found 3 abstracts

Adams GP, Simmons HH, Yuan Q, Marasco W, Mehta S. Anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer. 2005 Jul 08;:80 pp.
Adams GP, Horak EM, Weiner LM, Marks JD. Bispecific scFv antibody molecules capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer. 2004 Apr 04;:57 pp.
Larue L. A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active Akt. 2004 Mar 26;:47 pp.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostate gland

Ovary Prostate gland Diagnosis (cancer Radionuclides Cosmids Stomach Antitumor agents Bacteriophage Human Mammary gland Pancreas Imaging (tumor unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (RIP (ribosome-inactivating protein)-antibody conjugated with unclassified) Epidermal growth factor receptors Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (HER4 unclassified) neu Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment unclassified) Peptides Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (linker mullerian inhibiting substance receptor MISIIR immunoconjugate human cancer unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (BCAR1 (breast cancer anti-estrogen resistance 1) Animal tissue Blood plasma Blood BSU (Biological study Gene Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (for antibody unclassified) Vimentins Role: BSU (Biological study-BIOL (Biological study) (as markers of epithelial to mesenchymal transition Epitopes screening tumor cell invasion metastasis Akt unclassified) Antibodies and Immunoglobulins Role: BSU (Biological study-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (labeled Urine Adhesion (cell to cell treatment of Carcinoma (cervix cell line Mammary gland (carcinoma Signal transduction (inhibitors unclassified) Hormone receptors Role: BSU (Biological study-BIOL (Biological study) (Mullerian-inhibiting hormone-type II PRP (Properties) Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (anti-MISIIR unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (momordins-antibody conjugated with unclassified) gag proteins Role: BSU (Biological study-BIOL (Biological study) method for screening compds) Animal cell line (Hep G2 Plasmids Intestine (colon Drug delivery systems (carriers Gene therapy Liver Protein motifs (PH (pleckstrin homol) domain Phage display library Imaging (NMR unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (PAP (pokeweed antiviral protein)-antibody conjugated with Animal cell line (HEP-3B unclassified) Toxins Role: BSU (Biological study-BIOL (Biological study) (antibody conjugated with Bladder BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (fragments-scFv anti-Mullerian inhibiting substance type II recep Animal cell line (constitutively active AKT expressing unclassified) Transcription factors Role: BSU (Biological study-BIOL (Biological study) (ZEB1-ZEB2 unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (desmoplakins-as markers of epithelial to mesenchymal transition Viral vectors Blood cell Drug delivery systems (immunoconjugates Lung anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer) nude Mus (athymic unclassified) Toxins Role: BSU (Biological study-BIOL (Biological study) (diphtheria-antibody conjugated with Salivary gland Adoptive immunotherapy Ricins Protein sequences bispecific antibody scFv EGFR family member cancer diagnosis therapy Epidermal growth factor receptors Ligands Scintigraphy unclassified) Growth factor receptors Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (erbB-3 Imaging agents cDNA sequences (anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer) unclassified) Transcription factors Role: BSU (Biological study-BIOL (Biological study) (Snail site lacking Post-translational processing (proteolytic Animal cell line (MCF-7 BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (bispecific unclassified) Toxins Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (cytotoxins Animal cell line (HuH-7 Genetic vectors Liposomes Peptide nucleic acids bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer) antibody conjugated with Drug delivery systems (prodrugs mesenchymal Cell morphology (epithelial-and fibroblast Lung (toxicity Plasmid vectors Chemotherapy (antibody conjugated with BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (bispecific scFv antibody Imaging agents (NMR contrast Drug delivery systems (liposomes Labels Abrins Viral vectors (bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer) Diagnosis (immunodiagnosis of EGFR protein family for diagnosis and treatment of cancer) DNA sequences Animal cell line (DU-145 Testis Positron-emission tomography unclassified) Cadherins Role: BSU (Biological study-BIOL (Biological study) (E- Melanoma Drugs Linking agents carcinoma Uterus (cervix-treatment of H157 18-HLE-FTC-133-ALVA-31-PL-3-PANC-1-AsPXC-1-BxPC-1-KP-3-MKN28-MKN45-MKN74-Ovca420-Ovca429-Ovca432-Ovca422-SCC13-SCC15-SK29-SK28-Mel 888-NBT II Fusion proteins Cytotoxic agents magnetic Spheres (beads-antibody conjugated with Gamma ray (emitters or (MISIIR) immunoconjugates to detect and treat cancer) Samples (biol or biopsy Molecules (effector antimetastatic Antitumor agents (antiinvasive Uterus (endometrium Thyroid gland (cell line unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (HEF1 (enhancer of filamentation 1) Molecular cloning Uterus (cervix Immunoassay (immunohistochem PRP (Properties) Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (single chain-Fv-anti-MISIIR antibody conjugated with Pseudomonas (exotoxin Chemotherapy Animal cell bispecific scFv antibody mols capable of binding to different epitopes aspirate Mammary gland (nipple method for screening compds controlling tumor cell invasion or metastasis using constitutively active Akt) MT2994 Animal cell line (ZR-75T-MCT Testis (treatment of unclassified) Promoter Role: BSU (Biological study-BIOL (Biological study) (E-cadherin Radiation (external beam
Last updated on Tuesday, July 07, 2020